Review
doi: 10.2478/acph-2013-0022.
Drug interactions with statins
- PMID: 24152892
- DOI: 10.2478/acph-2013-0022
Item in Clipboard
Review
Drug interactions with statins
Acta Pharm.
2013 Sep.
Free article
Abstract
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are generally well tolerated as monotherapy. Statins are associated with two important adverse effects, asymptomatic elevation in liver enzymes and myopathy. Myopathy is most likely to occur when statins are administered with other drugs. Statins are substrates of multiple drug transporters (including OAT- -P1B1, BCRP and MDR1) and several cytochrome P450 (CYP) enzymes (including CYP3A4, CYP2C8, CYP2C19, and CYP2C9). Possible adverse effects of statins can occur due to interactions in concomitant use of drugs that substantially inhibit or induce their methabolic pathway. This review summarizes the most important interactions of statins.
Similar articles
-
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.Pharmacol Ther. 2006 Oct;112(1):71-105. doi: 10.1016/j.pharmthera.2006.03.003. Epub 2006 May 22. Pharmacol Ther. 2006. PMID: 16714062 Review.
-
Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.Curr Opin Investig Drugs. 2010 Mar;11(3):323-32. Curr Opin Investig Drugs. 2010. PMID: 20178046 Review.
-
Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.Clin Pharmacokinet. 2002;41(5):343-70. doi: 10.2165/00003088-200241050-00003. Clin Pharmacokinet. 2002. PMID: 12036392 Review.
-
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.Clin Pharmacol Ther. 2006 Dec;80(6):565-81. doi: 10.1016/j.clpt.2006.09.003. Clin Pharmacol Ther. 2006. PMID: 17178259 Review.
-
[Transplant coronary artery disease--treatment with statins].Pol Merkur Lekarski. 2004 May;16(95):472-3. Pol Merkur Lekarski. 2004. PMID: 15518430 Review. Polish.
Cited by
-
In vitro antibacterial effects of statins against bacterial pathogens causing skin infections.Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1125-1135. doi: 10.1007/s10096-018-3227-5. Epub 2018 Mar 22. Eur J Clin Microbiol Infect Dis. 2018. PMID: 29569046
-
Molecular targets of statins and their potential side effects: Not all the glitter is gold.Eur J Pharmacol. 2022 May 5;922:174906. doi: 10.1016/j.ejphar.2022.174906. Epub 2022 Mar 20. Eur J Pharmacol. 2022. PMID: 35321818 Free PMC article. Review.
-
An unusually impressive atorvastatin-induced elevation of serum alkaline phosphatase.BMJ Case Rep. 2020 Feb 10;13(2):e231839. doi: 10.1136/bcr-2019-231839. BMJ Case Rep. 2020. Corrected and republished in: Drug Ther Bull. 2021 Mar;59(3):43-47. doi: 10.1136/dtb.2020.231839rep. PMID: 32047080 Free PMC article. Corrected and republished.
-
Roles of Cofactors in Drug-Induced Liver Injury: Drug Metabolism and Beyond.Drug Metab Dispos. 2022 May;50(5):646-654. doi: 10.1124/dmd.121.000457. Epub 2022 Feb 27. Drug Metab Dispos. 2022. PMID: 35221288 Free PMC article. Review.
-
Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration.Clin Pharmacokinet. 2024 Apr;63(4):483-496. doi: 10.1007/s40262-024-01352-9. Epub 2024 Feb 29. Clin Pharmacokinet. 2024. PMID: 38424308 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
